Explore the efficacy and safety of targeted small molecule drug TYK2 inhibitors in combination with and without calcipotriol betamethasone for the treatment of adult moderate to severe plaque psoriasis.

开始日期2024-11-01

申办/合作机构-

CTR20223222

/ Completed临床3期

一项在中国稳定性斑块状银屑病成人受试者中比较LEO 90100和得肤宝 ®软膏治疗4周的有效性和安全性的III期、随机、研究者设盲、活性药物对照、平行分组、多中心试验

主要目的：评价LEO 90100与得肤宝®软膏相比对稳定性斑块状银屑病严重程度和范围的有效性。次要目的：评价LEO 90100与得肤宝®软膏相比治疗稳定性斑块状银屑病的安全性。

开始日期2023-06-21

申办/合作机构

LEO Laboratories Ltd.

[+2]

NCT05919082

/ Completed临床3期

A Phase 3, Randomised, Investigator-blind, Active-controlled, Parallel Group, Multicentre Trial Comparing the Efficacy and Safety of 4-weeks Treatment With LEO 90100 and Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis

This study is conducted to assess the efficacy and safety of LEO 90100 when used on the body for the treatment of stable plaque psoriasis in native adult Chinese subjects, compared to Daivobet® ointment.

开始日期2023-06-21

申办/合作机构

Leo Pharma, Inc.

100 项与倍他米松二丙酸酯/卡泊三醇相关的临床结果

登录后查看更多信息

100 项与倍他米松二丙酸酯/卡泊三醇相关的转化医学

登录后查看更多信息

100 项与倍他米松二丙酸酯/卡泊三醇相关的专利（医药）

登录后查看更多信息

项与倍他米松二丙酸酯/卡泊三醇相关的文献（医药）

2024-03-01·Dermatology and therapy

Improvements in Plaque Psoriasis Associated with Calcipotriol/Betamethasone Aerosol Foam Treatment: A Post Hoc Analysis of Non-interventional Studies and Clinical Experience

Article

作者: Jablonski Bernasconi, Marie Y ; Halioua, Bruno ; Lazaridou, Elizabeth ; Krogager Eeg, Martin ; Pesiridis, Georgios ; Campanati, Anna ; Ratzinger, Gudrun ; Gerdes, Sascha

INTRODUCTION:

Plaque psoriasis is a chronic relapsing inflammatory skin disease that is associated with extensive disease burden that often requires long-term therapy. Treatment of psoriasis with 4 weeks of the aerosol foam formulation of calcipotriol/betamethasone dipropionate (Cal/BD; Enstilar®, LEO Pharma) has been demonstrated to be effective, well tolerated, and associated with high patient satisfaction. Cal/BD foam is approved as a first-line treatment in multiple countries, where several non-interventional studies (NIS) have corroborated the beneficial efficacy and safety profiles determined in the randomized clinical trials. Heterogenicity in these NIS, however, prevents the use of a data pooling strategy for comparisons of effectiveness outcomes across different patient populations.

METHODS:

Therefore, here, we report on a post hoc analysis of effectiveness data consolidated from six prospective NIS to discern any differences in improvement in signs and symptoms of psoriasis attributable to Cal/BD foam treatment across the countries. In addition, we provide real-world experience of clinicians with Cal/BD foam treatment, factoring in changes in usage since these NIS were performed in their local markets.

RESULTS:

This post hoc analysis of Cal/BD foam NIS brings together data outside of randomized clinical trials from six countries to provide real-world evidence in 1388 patients showing that 4 weeks of Cal/BD foam is an effective and safe treatment option with quick onset of action for patients with psoriasis.

CONCLUSION:

These results show that regardless of NIS location, Cal/BD foam remains a well-tolerated, efficacious option for patient care that could be used as a first-line topical therapy for mild-to-severe psoriasis.

2023-12-31·The Journal of dermatological treatment

Potential biomarkers for psoriasis topical treatment by in-depth serum proteomics

Article

作者: Yu, Xiaobo ; Deng, Hao ; Lu, Chuanjian ; Zhang, Xiaomei ; Yu, Jingjie ; Yao, Danni ; Cui, Jingwen ; Deng, Jingwen ; Ye, Shuyan ; Han, Ling ; Yan, Yuhong

BACKGROUND:

Psoriasis is a chronic skin disease, and topical sequential therapy with a combination of calcipotriol and calcipotriol betamethasone is currently approved topical treatment. However, the exact mechanism by which this treatment regimen relieves psoriasis is unknown.

METHOD:

We assembled a cohort of 65 psoriasis patients and divided post-treatment cohort into responder group and non-responder group according to the Psoriasis Area Severity Index (PASI) score after 12-week treatment. We measured the expression levels of proteins in collected 130 serum samples using our in-depth proteomics platform with a data-independent acquisition mass spectrometer and antibody microarray. We performed bioinformatics analyses of the biologic processes and signaling pathways that were changed in the responder group and constructed a proteomics landscape of psoriasis pathogenesis response to treatment. We then validated the biomarkers of disease severity in an independent cohort of 88 samples using an enzyme-linked immunosorbent assay.

RESULTS:

We first identified 174 differentially expressed proteins (DEPs) for comparative analysis of proteins between responders and non-responders at baseline (p < 0.05). Then pathway analysis showed that the responders focused more on signaling molecules and interaction, complement and coagulation cascades, whereas the non-responders more on signal transduction and IL-17 signaling pathways. We further identified four candidate biomarkers (COLEC11, C1QA, BNC2, ITIH4) response to treatment. We also found 125 DEPs (p < 0.05) after treatment compared with before treatment in responder group. Pathway analysis showed an enrichment in pathways related to complement and coagulation cascades, phagosome, ECM-receptor interaction, cholesterol metabolism, vitamin digestion and absorption. CD14 was validated as potential biomarkers for the disease severity of psoriasis and treatment targets.

CONCLUSION:

In this work, we analyzed the response to topical sequential therapy and finally identified four biomarkers. Additionally, we found that topical sequential therapy may alleviate psoriasis by regulating lipid metabolism and modulating the immune response by affecting the complement activation process.

2023-11-01·European review for medical and pharmacological sciences

The role of the foam formulation in improving psoriasis treatment acceptability: a real-life experience and a literature review.

Review

作者: Papa, S ; Gasparini, S ; Martella, A ; Giovene, G L

BACKGROUND:

Topical therapies represent the first-line treatment for mild-to-moderate psoriasis. Among various topical options, the fixed-dose combination of calcipotriene (Cal) and betamethasone dipropionate (BD) foam (Enstilar®, LEO Pharma, Ballerup, Denmark) showed superior efficacy to Cal and BD monotherapy and ointment and gel formulations. In addition, the Cal/BD foam is the only topical treatment allowed for either reactive treatment of relapse or twice-weekly maintenance use. Since treatment acceptability is crucial to optimize adherence, this paper presents a case series from a multicenter experience using the Cal/BD foam, to further characterize the use of this therapeutic approach. In addition, a narrative review of studies evaluating the acceptability of the Cal/BD foam, even compared with other formulations, is provided.

CASE SERIES:

The case series involved adult patients with mild-to-moderate psoriasis treated with the Cal/BD foam from October 2021 to June 2022. A clinical and dermoscopic evaluation of plaques was provided for all patients. Data from the clinical practice report complete clinical resolution of plaques in most patients after 4 weeks of active treatment with the Cal/BD foam, and the dermoscopic clearance after a maximum of 8 weeks. Full adherence to treatment was also reported. Literature evidence suggests that the Cal/BD foam is easy to apply and presents high cosmetic acceptance, rapid onset of action, high efficacy, optimal safety, and a high patient preference. The high satisfaction obtained with Cal/BD foam suggests that this formulation is better accepted than others.

CONCLUSIONS:

The Cal/BD foam represents a valuable approach for managing mild-to-moderate psoriasis, both in short and long-term treatment.

项与倍他米松二丙酸酯/卡泊三醇相关的新闻（医药）

2025-03-28

·PMLiVE

LEO and Reig Jofre partner to improve access to psoriasis therapy in Europe

L-R: Ignasi Biosca, CEO of Reig Jofre, and Juan Fran Cuello de Oro, general manager of LEO Pharma Iberia LEO Pharma and Reig Jofre have entered into a partnership aimed at improving access to LEO’s psoriasis treatment in Europe. The commercial agreement will focus on strengthening the promotion of Enstilar, an aerosol spray foam containing the vitamin D analogue calcipotriol and betamethasone dipropionate, for mild-to-moderate psoriasis within the scope of primary care across Spain. Approximately 125 million people worldwide are affected by some form of psoriasis, a chronic inflammatory condition that typically affects the skin, nails and joints. Up to 90% of patients have plaque psoriasis, characterised by distinct round or oval plaques typically covered by silvery-white scales. LEO’s fixed-dose combination therapy is designed to improve anti-psoriatic response in patients and has been recognised by Farmaindustria, the national association of the pharmaceutical industry in Spain, as an “incremental innovation” due to its advanced foam-based formulation. The collaboration between LEO and Reig Jofre will help extend the treatment’s reach, improve patient access and enhance support for healthcare professionals. “This agreement marks a significant milestone in positioning Reig Jofre and LEO Pharma as key players in medical dermatology in Spain,” Reig Jofre outlined in a statement, adding that the partnership “ensures that healthcare professionals receive the support, proximity and information needed to provide the best possible care to their patients”. LEO has already entered into a number of partnerships this year. Last month, it announced a collaboration with non-profit organisation DEBRA Research aimed at accelerating the development of treatments for epidermolysis bullosa, a group of rare and painful inherited skin disorders that cause the skin to become very fragile and tear or blister very easily. Though financial details of the alliance were not disclosed, the partners said they are hoping to “enhance scouting capabilities and provide additional capacity to accelerate the development of life-changing therapies for epidermolysis bullosa”. The company also partnered with Gilead Sciences in January to advance its small molecule oral STAT6 programme for inflammatory diseases. The deal, worth $1.7bn, gave Gilead global rights to develop, manufacture and commercialise the oral STAT6 programme. Meanwhile, LEO will hold exclusive global rights to STAT6 topical formulations in dermatology, and will have the option to co-commercialise oral programmes for dermatology indications outside the US.

引进/卖出

2024-12-18

·华东医药股份有限公司

华东医药创新皮肤外用制剂罗氟司特乳膏两项Ⅲ期临床试验完成首例受试者入组

近日，华东医药股份有限公司（以下简称“公司”）全资子公司杭州中美华东制药有限公司（以下简称“中美华东”）开展的评价0.15%罗氟司特乳膏（ZORYVE®）在轻中度特应性皮炎患者中有效性和安全性的多中心、随机、双盲、赋形剂对照的Ⅲ期桥接研究在上海复旦大学附属华山医院完成首例受试者入组及给药；一项多中心、随机、双盲、赋形剂对照的评价0.3%罗氟司特乳膏（ZORYVE®）治疗中国斑块状银屑病的有效性和安全性的Ⅲ期临床研究在北京大学人民医院完成首例受试者入组及给药。罗氟司特是一种磷酸二酯酶-4（PDE4）抑制剂，可增加促炎介质的生成并减少抗炎介质的生成，抑制PDE4可减轻炎症反应。罗氟司特乳膏是中美华东与美国纳斯达克上市公司Arcutis Biotherapeutics, Inc.（NASDAQ: ARQT）（以下简称“Arcutis”）于2023年8月签署合作协议引进的创新皮肤外用制剂产品，中美华东拥有该产品在大中华区及东南亚的独家许可。0.3%罗氟司特乳膏（ZORYVE®）于2022年7月获得美国FDA批准，用于治疗12岁及以上患者的斑块状银屑病，2023年4月在加拿大获批相同适应症，2023年10月在美国获批斑块状银屑病适应症扩展人群至6-11岁儿科人群；0.15%罗氟司特乳膏（ZORYVE®）于2024年7月获得美国FDA批准，用于治疗6岁及以上患者的轻度至中度特应性皮炎。在银屑病治疗领域，公司目前已布局生物制剂乌司奴单抗注射液、口服小分子药物环孢素软胶囊、单方外用制剂ZORYVE®乳膏剂和泡沫剂以及复方外用制剂Wynzora®乳膏，形成了多靶点、多作用机制的银屑病产品组合，可实现全周期全人群覆盖。其中，公司乌司奴单抗注射液（赛乐信®）（研发代码：HDM3001/QX001S）的上市许可申请在2024年10月获得批准，用于治疗成年中重度斑块状银屑病，为国产首家，儿童斑块状银屑病的补充申请于2024年12月获得受理。本次0.15%罗氟司特乳膏和0.3%罗氟司特乳膏两项Ⅲ期临床试验均完成了首例受试者入组，是产品研发进程中的重要里程碑，将进一步提高公司在自身免疫性及炎症性皮肤病领域的核心竞争力。公司后续将继续全力推进该款产品的临床开发及注册工作，争取为中国银屑病和特应性皮炎临床患者提供更多的治疗选择。声明 1、本新闻旨在分享公司（或合作伙伴）研发工作的前沿进展资讯，非广告用途，相关信息并非针对患者，仅供医疗卫生专业人士参考使用； 2、本新闻稿中内容不涉及对任何药品和/或适应症作推荐； 3、本新闻稿中涉及的信息仅供参考，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。 4、截止本文发布，0.15%罗氟司特乳膏（ZORYVE®）与0.3%罗氟司特乳膏（ZORYVE®）尚未被国家药品监督管理局批准上市； 5、本新闻稿中可能会包含某些前瞻性表述。这些表述本质上具有相当风险和不确定性。在使用“预期”、“相信”、“预测”、“期望”、“打算”及其他类似词语进行表述时，凡与本公司有关的，均属于前瞻性表述。本公司并无义务不断地更新这些预测性陈述。这些前瞻性表述是基于本公司管理层在做出表述时对未来事务的现有看法、假设、期望、估计、预测和理解。这些表述并非对未来发展的保证，会受到风险、不确性及其他因素的影响，有些是超出本公司的控制范围，难以预计。因此，受我们的业务、竞争环境、政治、经济、法律和社会情况的未来变化及发展的影响，实际结果可能会与前瞻性表述所含资料有较大差别。本公司、本公司董事及雇员代理概不承担 (a) 更正或更新本网站所载前瞻性表述的任何义务;及 (b) 若因任何前瞻性表述不能实现或变成不正确而引致的任何责任。

临床3期上市批准

2024-11-20

·药事纵横

盐酸米诺环素泡沫剂获批上市，国内泡沫剂研发竞赛拉开序幕

一、背景 2024年11月05日，科笛生物医药（上海）有限公司「盐酸米诺环素泡沫剂」(规格：4%)获得中国国家药品监督管理局（NMPA）批准在中国上市，用于治疗九岁或以上患者的非结节性中度至重度寻常痤疮炎症性病变的局部治疗。据笔者了解，该药获得了国家药监局药品审评中心优先审评审批资格。这是目前国内批准的首款盐酸米诺环素外用制剂，也是首款在国内上市销售的原研进口泡沫剂产品。 4%盐酸米诺环素泡沫剂（商品名：Amzeeq®）最早是由位于以色列的一家专门从事泡沫剂产品开发的制药公司Foamix Pharmaceuticals（2020年与Menlo Therapeutics合并成为其全资子公司）研发，于2019年10月18日被美国食品药品监督管理局（FDA）批准上市。2020年4月，Foamix与科笛生物（Cutia Therapeutics）达成协议，将包括Amzeeq®盐酸米诺环素泡沫剂在内的多个盐酸米诺环素外用制剂产品在大中华区的独家许可权授予科笛生物，向科笛供应用于临床和商业用途的许可产品。根据公开的信息，Foamix通过该授权可获得1000万美元的预先现金付款，产品一旦在中国获批上市销售，还将获得额外的100万美元付款。此外，根据协议Foamix还会根据科笛在大中华区销售这些被许可产品的净销售额，获得一定比例的版税收入。科笛生物于2021年在中国境内开展了一项评价盐酸米诺环素泡沫剂（4%）局部给药治疗中度至重度寻常痤疮的多中心、随机、双盲、安慰剂对照的有效性和安全性的III期注册性临床试验。研究结果显示，经过12周后治疗后，治疗炎性皮损的改善相较于安慰剂组展现出了显著的改善，达到主要终点指标。在安全性方面，治疗组受试者对给药部位局部表现出了良好的耐受性。治疗组与安慰剂组在不良事件的总发生率上相当，且均未报告有药物相关的严重不良事件。口服盐酸米诺环素治疗痤疮疗效较差且容易引起全身的毒副作用，而4%盐酸米诺环素泡沫剂作为的首款盐酸米诺环素的外用制剂成功实现了盐酸米诺环素的局部外用给药，不仅疗效显著且大大降低了口服给药带来的不良反应，具有里程碑意义。笔者曾于2023年9月在本公众号（“药事纵横”）上发表了《浅析盐酸米诺环素油泡沫剂处方设计及泡沫形成原理》一文，简要介绍了盐酸米诺环素外用制剂开发面临的挑战以及其泡沫剂处方及发泡原理。具体来说，Foamix利用了其独特的分子稳定技术（Molecular Stabilizing Technology, MST）技术，有效解决了盐酸米诺环素药物的稳定性（如对光、氧、水、某些质子性溶剂和表面活性剂等不稳定）问题，成功开发出了无水、无表面活性剂的盐酸米诺环素泡沫剂。该技术将微粉化的盐酸米诺环素分散在大量的油性基质中，利用抛射剂汽化后处方中高级脂肪醇和高级脂肪酸吸附空气-油界面，形成稳定的油泡沫，方便患者涂抹于患处。二、关于泡沫剂泡沫剂（foam）是指将原料药和辅料灌装到加压容器或者非加压容器后将内容物呈泡沫状喷出一类药物制剂。前者需要填充抛射剂才能形成在喷出后形成泡沫，因此又称“泡沫气雾剂”（foam aerosol）。在国内，一般提到泡沫剂都默认指的是泡沫气雾剂。泡沫剂具有吸附性强、易于涂布、美观、经皮渗透能力强等优点。此外，对于腔道给药，泡沫剂给药后泡沫能够迅速在腔道内（如阴道、直肠等）充盈，覆盖给药部位，给药便捷，这是很多传统剂型所不具备的优势。美国FDA迄今已批准了18种泡沫剂NDA上市申请，其最早批准的一款泡沫剂产品可以追溯到1999年上市的戊酸倍他米松泡沫剂（见本公众号文章《盘点泡沫气雾剂给药系统中应用的平台技术》）。目前除了盐酸米诺环素泡沫剂的进口上市申请已经获批，笔者注意到利奥制药（LEO Pharma）也于近期正式向国家药品管理局提交了Enstilar®泡沫剂（卡泊三醇/丙酸倍他米松泡沫剂）进口上市许可申请。在国内，2023年12月中国药品监督管理局才批准第一款化药泡沫剂产品——米诺地尔泡沫剂仿制药上市。截至目前，尚没有一款国内企业自主研发的泡沫剂NDA上市申请获批。但是，从国家药品监督管理局药品审评中心CDE受理品种目录可以看出，国内泡沫剂国内泡沫剂研发竞赛已经悄然拉开了序幕。最近两年最为热门的泡沫剂仿制品种当属米诺地尔泡沫剂和盐酸米诺环素泡沫剂。目前CDE已经受理了浙江三生蔓迪药业有限公司（已获批）、辰光（天津）制药有限公司、山西振东安欣生物制药有限公司、山东致泰医药技术有限公司/济宁为民制药有限公司、广东红珊瑚药业有限公司等5家公司的米诺地尔泡沫剂仿制药上市申请。而山西振东安欣的盐酸米诺环素泡沫剂仿制药上市申请也于今年6月份获得CDE受理。可以看出，目前国内药企于泡沫剂这一剂型的重视程度和研发热情较前些年有了明显的高涨。这其中的热情并不难理解。米诺地尔作为一种有效的脱发治疗药物，其泡沫剂型相比传统搽剂具有更好的使用体验和患者依从性。随着脱发问题的日益普遍和年轻化，米诺地尔泡沫剂的市场需求持续增长。而盐酸米诺环素泡沫剂在治疗痤疮方面显示出良好的疗效和安全性，且痤疮是一种常见的皮肤问题，尤其在青少年和年轻成人中发病率较高，因此该药物的市场需求也很大。此外，泡沫剂作为一种高端药物递送系统，处方工艺复杂，仿制难度大，进入壁垒高，一旦成功研发并上市，将能够在一定程度上避免激烈的市场竞争。且由于泡沫剂研发难度大、成本高，市场上同类竞品相对较少，这有助于产品在市场上占据一定的份额，并享受较高的利润空间。与传统仿制药相比，泡沫剂这种高端制剂由于技术壁垒和独特优势，受集采政策的影响相对较小，这就意味着在集采压力下，其仍能保持一定的价格优势和市场竞争力。三、结语随着米诺地尔泡沫剂、盐酸米诺环素泡沫剂的相继获批上市，国内泡沫剂市场正式迎来了一个全新的竞争格局。这两款产品的上市到来不仅为患者提供了更多的治疗选择，也将极大地激发国内药企对泡沫剂研发的热情和动力。可以预见，在未来将会有更多的泡沫剂产品涌现市场，为患者带来福音，这也将促使国内药企在泡沫剂研发创新、质量控制、市场推广等方面不断提升自身实力，推动企业自身发展和中国医药产业进步。药事纵横征稿启事

优先审批上市批准临床3期引进/卖出医药出海

100 项与倍他米松二丙酸酯/卡泊三醇相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	D05AX52	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
头皮银屑病	英国	Almirall SA	2021-07-29
银屑病	瑞士	LEO Pharma A/S	2008-09-04
斑块状银屑病	美国	LEO Pharma A/S	2008-05-09
寻常性银屑病	美国	LEO Pharma A/S	2006-01-09

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
银屑病关节炎	临床2期	法国	Leo Pharma, Inc.	2009-01-01
过敏性皮肤反应	临床1期	美国	MC2 Therapeutics Ltd.	2019-02-27
红斑	临床1期	日本	Leo Pharma, Inc.	2015-03-01
晒伤	临床1期	日本	Leo Pharma, Inc.	2015-03-01
光毒性皮炎	临床1期	日本	Leo Pharma, Inc.	2010-12-01
瘙痒	临床1期	日本	Leo Pharma, Inc.	2010-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05919082 (CTgov)	临床3期	斑块状银屑病	604	LEO 90100 (LEO 90100)	構構製繭鹹願願襯選積 = 齋壓觸顧餘壓憲積鬱觸製憲積願遞淵廠醖廠願 (衊淵築艱選鏇獵淵選蓋, 鏇顧鑰製製顧膚齋艱窪 ~ 願壓壓顧製積餘襯鹹選) 更多	-	2025-03-21
				Daivobet® ointment (Daivobet® Ointment)	構構製繭鹹願願襯選積 = 範鏇醖願觸糧觸築鹽糧製憲積願遞淵廠醖廠願 (衊淵築艱選鏇獵淵選蓋, 艱窪窪鬱齋淵遞鑰餘簾 ~ 積鬱鏇積齋醖繭遞窪繭) 更多
NCT04227288 (CTgov)	临床4期	甲银屑病	6	Enstilar Foam	餘窪構襯構膚夢鑰獵繭 = 膚願鑰鹹艱鹽憲窪鬱製遞糧築憲願膚願衊顧糧 (繭觸製鏇選齋網鏇膚窪, 鑰蓋醖顧鬱衊膚選簾憲 ~ 壓積鬱鹽齋顧製鬱膚蓋) 更多	-	2025-01-17
NCT05919082 (NEWS) 人工标引	临床3期	斑块状银屑病	604	LEO 90100	衊觸艱壓鬱鬱網鑰鑰製(醖鏇獵範艱簾齋窪窪淵) = Enstilar®在主要终点上相较于得肤宝®（卡泊三醇倍他米松软膏）表现出优效性顧鏇鬱糧壓願襯鑰醖網 (鹹壓艱鑰壓觸廠範簾鹽 ) 达到更多	积极	2024-05-08
				得肤宝
NCT03308799 (Biospace) 人工标引	临床3期	皮肤色素沉着	-	Calcipotriene+Betamethasone Dipropionate/Calcipotriene (Patients with skin of color (Fitzpatrick IV-VI))	艱襯構顧壓簾鑰醖鏇鏇(鏇淵願積糧鏇衊遞鬱廠) = 遞顧觸願範選築鏇積網鬱網繭鏇繭選鑰蓋窪齋 (壓壓餘夢艱鬱範衊鹹顧 ) 更多	积极	2022-09-15
Pubmed 人工标引	N/A	寻常性银屑病	166	Calcipotriene+LEO90100	製餘憲顧範願鏇淵積鏇(願憲構窪觸壓淵膚構膚) = 夢鹹窪製築襯範衊積窪簾窪鑰繭鬱範積鏇餘選 (鹽窪範蓋膚選襯窪鹽遞, 3.0) 更多	积极	2022-07-18
NCT02668692 (CTgov)	临床3期	寻常性银屑病	213	LEO 80185 gel	蓋簾膚鏇蓋憲獵醖鹽淵(選醖觸糧壓艱鏇齋選憲) = 夢顧蓋觸遞鏇顧觸齋獵鑰淵遞觸壓願鹽壓淵選 (醖構糧鹽構選壓窪鏇齋, 1.91) 更多	-	2021-07-27
NCT02899962 (PSO-LONG trial, Pubmed \| J Am Acad Dermatol) 人工标引	临床3期	斑块状银屑病	545	Cal/BD foam	艱鹽鬱顧襯選鹹餘顧網(願積簾廠鬱觸鹽齋廠網) = 膚蓋製鬱製夢艱齋醖遞鏇鏇膚夢顧廠夢繭壓範 (襯鬱網觸鑰願觸鑰選簾 ) 更多	优效	2021-05-01
				vehicle foam	艱鹽鬱顧襯選鹹餘顧網(願積簾廠鬱觸鹽齋廠網) = 簾齋鑰齋鏇選觸繭廠壓鏇鏇膚夢顧廠夢繭壓範 (襯鬱網觸鑰願觸鑰選簾 ) 更多
NCT03819218 (CTgov)	临床2期	寻常性银屑病	7	MC2-01 cream	製餘襯觸鹹艱構廠願壓 = 齋繭壓膚積範艱鹽壓製衊醖簾遞簾糧壓醖糧醖 (鹹積鹽築壓淵鹹醖網網, 膚衊艱鬱鏇選築鏇選鏇 ~ 選鏇淵淵艱鑰蓋憲糧簾) 更多	-	2021-02-21
NCT03506477 (CTgov)	临床4期	斑块状银屑病	25	Enstilar® foam (Enstilar® Foam)	醖顧鹹繭鬱壓餘鑰艱憲 = 膚齋鑰夢觸積憲鹹積構鑰鏇鹽淵繭蓋艱積顧齋 (鑰願鹽艱憲鑰繭範願齋, 夢窪鏇築願網鹽鹽願壓 ~ 壓鹽衊鑰繭齋窪糧衊鏇) 更多	-	2021-01-20
				Vehicle Foam (Vehicle Foam)	醖顧鹹繭鬱壓餘鑰艱憲 = 憲蓋範範鹹鏇淵構選鹹鑰鏇鹽淵繭蓋艱積顧齋 (鑰願鹽艱憲鑰繭範願齋, 積獵糧構淵蓋築壓餘顧 ~ 積窪製顧襯夢蓋鑰窪齋) 更多
NCT03806790 (CTgov)	临床3期	寻常性银屑病	182	LEO 90100 foam (LEO 90100 Foam)	鹹廠醖網壓鹹蓋鑰鏇網 = 襯獵顧構鑰膚淵簾選觸廠蓋構壓願淵壓窪鏇願 (構壓廠鹽觸製膚艱蓋襯, 鹽製觸築襯艱衊構襯淵 ~ 鑰壓簾鏇鏇衊願憲鏇膚) 更多	-	2020-12-16
				Dovobet® ointment (Dovobet® Ointment)	鹹廠醖網壓鹹蓋鑰鏇網 = 廠廠鬱鹹鏇壓壓鏇蓋衊廠蓋構壓願淵壓窪鏇願 (構壓廠鹽觸製膚艱蓋襯, 積製夢鏇選糧積衊夢齋 ~ 鏇鑰憲蓋淵齋觸遞顧齋) 更多